Please login to the form below

Procoralan

This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.

The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.

FDA clears Amgen's Corlaner for heart failure

Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
Amgen gets priority review for chronic heart failure hope

require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Amgen throws its hat into the cholesterol antibody ring

Procoralan (ivabradine) from Servier in July.
Amgen drug misses endpoint in acute heart failure trial

a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
Amgen buys US rights to Servier’s Procoralan

The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has obtained US rights to for an upfront fee of $50m plus undisclosed future milestones and royalties

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Heart failure therapy embarks on a new era

has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
Deal Watch table for July 2013

100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Add my company

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...